Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8<sup>+</sup> T cells

Kathryn M LaPorte(University of Miami), Thomas R. Malek(University of Miami)
Journal for ImmunoTherapy of Cancer
June 1, 2023
Cited by 27


Related Papers